Advanced

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer

Semenas, Julius LU ; Dizeyi, Nishtman LU and Persson, Jenny L LU (2013) In Drug Design, Development and Therapy 7. p.875-881
Abstract
Prostate cancer (PCa) is the most common malignancy, and the third leading cancer-related cause of death among men of the Western world. Upon PCa progression into metastatic disease, androgen deprivation therapy is applied as the first-line treatment, and has been shown to be effective in most patients, leading to a decrease in serum prostate-specific antigen and relief of disease-related symptoms. However, advanced PCa almost inevitably progresses to a castration-resistant state, and is currently regarded as incurable. The large body of evidence indicates that PCa cells remain dependent on androgen receptor (AR) signaling even in an androgen-deprived environment. As such, development of drugs that target AR and AR signaling pathways have... (More)
Prostate cancer (PCa) is the most common malignancy, and the third leading cancer-related cause of death among men of the Western world. Upon PCa progression into metastatic disease, androgen deprivation therapy is applied as the first-line treatment, and has been shown to be effective in most patients, leading to a decrease in serum prostate-specific antigen and relief of disease-related symptoms. However, advanced PCa almost inevitably progresses to a castration-resistant state, and is currently regarded as incurable. The large body of evidence indicates that PCa cells remain dependent on androgen receptor (AR) signaling even in an androgen-deprived environment. As such, development of drugs that target AR and AR signaling pathways have become one of the major milestones in treatment of castration-resistant PCa (CRPC). Nevertheless, currently available therapies that target AR signaling are still regarded as palliative and more potent therapies are in great need. Over the past few years, a wide range of novel therapies has entered clinical trial for treatment of CRPC, including androgen synthesis inhibitors (abiraterone acetate), chemotherapeutic agents (docetaxel and cabazitaxel), and immunotherapies (sipuleucel-T). In this context, enzalutamide (previously referred to as MDV3100) is a novel second generation antiandrogen that has been demonstrated to significantly improve survival in men with metastatic CRPC in several clinical trials. In this paper we summarize recently completed and ongoing clinical trials of enzalutamide, and briefly discuss the efficacy of the novel antiandrogen therapy and its limitations for treatment of CRPC. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
castration resistant prostate cancer, drug resistance, clinical trials
in
Drug Design, Development and Therapy
volume
7
pages
875 - 881
publisher
Dove Medical Press Ltd.
external identifiers
  • wos:000323479200001
  • scopus:84883249583
  • pmid:24009414
ISSN
1177-8881
DOI
10.2147/DDDT.S45703
language
English
LU publication?
yes
id
cb4fe63e-0196-4e51-a447-222e0f3dd263 (old id 4027023)
date added to LUP
2016-04-01 12:53:24
date last changed
2019-12-10 02:52:29
@article{cb4fe63e-0196-4e51-a447-222e0f3dd263,
  abstract     = {Prostate cancer (PCa) is the most common malignancy, and the third leading cancer-related cause of death among men of the Western world. Upon PCa progression into metastatic disease, androgen deprivation therapy is applied as the first-line treatment, and has been shown to be effective in most patients, leading to a decrease in serum prostate-specific antigen and relief of disease-related symptoms. However, advanced PCa almost inevitably progresses to a castration-resistant state, and is currently regarded as incurable. The large body of evidence indicates that PCa cells remain dependent on androgen receptor (AR) signaling even in an androgen-deprived environment. As such, development of drugs that target AR and AR signaling pathways have become one of the major milestones in treatment of castration-resistant PCa (CRPC). Nevertheless, currently available therapies that target AR signaling are still regarded as palliative and more potent therapies are in great need. Over the past few years, a wide range of novel therapies has entered clinical trial for treatment of CRPC, including androgen synthesis inhibitors (abiraterone acetate), chemotherapeutic agents (docetaxel and cabazitaxel), and immunotherapies (sipuleucel-T). In this context, enzalutamide (previously referred to as MDV3100) is a novel second generation antiandrogen that has been demonstrated to significantly improve survival in men with metastatic CRPC in several clinical trials. In this paper we summarize recently completed and ongoing clinical trials of enzalutamide, and briefly discuss the efficacy of the novel antiandrogen therapy and its limitations for treatment of CRPC.},
  author       = {Semenas, Julius and Dizeyi, Nishtman and Persson, Jenny L},
  issn         = {1177-8881},
  language     = {eng},
  pages        = {875--881},
  publisher    = {Dove Medical Press Ltd.},
  series       = {Drug Design, Development and Therapy},
  title        = {Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer},
  url          = {https://lup.lub.lu.se/search/ws/files/3030393/4249456.pdf},
  doi          = {10.2147/DDDT.S45703},
  volume       = {7},
  year         = {2013},
}